文献速递精神分裂症与精神病性障碍会诊联络精神医学

抗NMDAR脑炎急性期后与精神分裂症脑代谢物水平的纵向病例对照研究

Brain Metabolite Levels in the Post-Acute Stage of Anti-NMDA Receptor Encephalitis and Schizophrenia: A Longitudinal Case-Control Study.
PubMed 文献 · Biol Psychiatry · 2025-07-12

该24个月前瞻性病例对照研究纳入12至60岁抗NMDAR脑炎急性期后患者、年龄性别匹配的精神分裂症患者及健康对照,用磁共振波谱检测左背内侧前额叶和内侧颞叶的谷氨酸能代谢物、肌醇及tNAA。结果发现抗NMDAR脑炎患者左dmPF谷氨酸和谷氨酸+谷氨酰胺显著低于精神分裂症和健康对照,而两组患者肌醇均高于健康对照。

要点

  • 抗NMDAR脑炎急性期后左dmPF存在谷氨酸能低下。
  • 抗NMDAR脑炎和精神分裂症均显示肌醇升高。
  • 代谢物水平与精神或认知症状无关联。

核心结论

  • 抗NMDAR脑炎急性期后左背内侧前额叶存在持续性谷氨酸能低下。
  • 抗NMDAR脑炎和精神分裂症均存在肌醇升高,提示重叠的神经炎症过程。

研究设计与样本

  • 24个月前瞻性病例对照研究,纳入12至60岁抗NMDAR脑炎急性期后患者、年龄性别匹配的精神分裂症患者和健康对照。
  • 采用单体素磁共振波谱检测左背内侧前额叶和内侧颞叶的谷氨酸能代谢物、肌醇和tNAA。
  • 使用多水平线性混合模型检验组别和时间对代谢物水平的影响及代谢物与精神认知特征的关系。

主要发现

  • 左dmPF谷氨酸水平在抗NMDAR脑炎患者中显著低于精神分裂症患者(Cohen's d=-0.87)和健康对照(d=-0.73)。
  • 左dmPF谷氨酸+谷氨酰胺水平在抗NMDAR脑炎患者中显著低于精神分裂症患者(d=-0.80)和健康对照(d=-0.71)。
  • 肌醇水平在抗NMDAR脑炎患者(d=0.91)和精神分裂症患者(d=1.07)中均显著高于健康对照。
  • 组间差异随时间保持稳定,代谢物水平与精神或认知症状无关联。

关键数值与推荐

  • 左dmPF谷氨酸组间效应量:抗NMDAR脑炎 vs 精神分裂症 d=-0.87,vs 健康对照 d=-0.73。
  • 左dmPF谷氨酸+谷氨酰胺组间效应量:抗NMDAR脑炎 vs 精神分裂症 d=-0.80,vs 健康对照 d=-0.71。
  • 肌醇组间效应量:抗NMDAR脑炎 vs 健康对照 d=0.91,精神分裂症 vs 健康对照 d=1.07。

临床怎么用

  • 左dmPF谷氨酸能低下可作为抗NMDAR脑炎急性期后持续神经代谢异常的潜在标志。
  • 肌醇升高在抗NMDAR脑炎和精神分裂症中均出现,提示两者可能共享神经炎症机制。
  • 代谢物水平与精神认知症状无关联,不建议用作症状严重度的替代指标。

局限性

  • 仅检测左背内侧前额叶和内侧颞叶两个脑区。
  • 代谢物水平与精神或认知症状无关联,未发现临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In vivo assessment of glutamatergic metabolites in patients with anti-NMDA receptor (anti-NMDAR) encephalitis compared with schizophrenia may help increase understanding of the pathophysiology of both conditions. METHODS: This 24-month prospective case-control study included participants ages 12 to 60 years with anti-NMDAR encephalitis during the post-acute stage and age- and sex-matched individuals with schizophrenia and healthy control participants (HCs). Single-voxel magnetic resonance spectroscopy was used to estimate brain concentrations of glutamatergic metabolites, myo-inositol, and N-acetylaspartate+N-acetylaspartylglutamate (tNAA) in the left dorsomedial prefrontal region (dmPF) and medial temporal lobe. The effect of group and time on metabolite levels and the relationship between metabolite levels and psychiatric and cognitive features were tested with multilevel linear mixed models. RESULTS: Thirty-two participants with anti-NMDAR encephalitis (84% women), 27 participants with schizophrenia (63% women), and 36 HCs (72% women) were included. In the dmPF, levels of glutamate and glutamate+glutamine were significantly lower in patients with anti-NMDAR encephalitis than in participants with schizophrenia (Cohen's d = -0.87 and d = -0.80, respectively) and HCs (d = -0.73 and d = -0.71). Myo-inositol levels were significantly higher in both participants with anti-NMDAR encephalitis (d = 0.91) and patients with schizophrenia (d = 1.07) than in HCs. Group differences remained stable over time. Metabolite levels were not associated with psychiatric or cognitive symptoms. CONCLUSIONS: This is the first report of hypoglutamatergia in the left dmPF in anti-NMDAR encephalitis and of increased levels of myo-inositol in both anti-NMDAR encephalitis and schizophrenia. The findings suggest persistent alterations in glutamatergic neurotransmission during the post-acute stage of anti-NMDAR encephalitis and overlapping neuroinflammatory processes between anti-NMDAR encephalitis and schizophrenia.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fortea A, Ortuño M, Masias M, et al. Brain Metabolite Levels in the Post-Acute Stage of Anti-NMDA Receptor Encephalitis and Schizophrenia: A Longitudinal Case-Control Study. Biol Psychiatry. 2025. PMID: 40659201. doi:10.1016/j.biopsych.2025.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。